A clinical study on the maintenance strategy of multiple myeloma after autologous hematopoietic stem cell transplantation based on the detection of minimal residual disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031516

Enrollment

Unknown

Registered

2020-04-03

Start date

2020-05-01

Completion date

Unknown

Last updated

2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

maintain treatment:bortezomib/lenalidomide

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. More than 18 years old and less than 65 years old,and no contraindication of ASCT; 2. MM patients with measurable disease according to the guidelines for the diagnosis and management of multiple myeloma in China (2017 revision); 3. ECOG > 3; 4. Patients with good physical and mental health.

Exclusion criteria

Exclusion criteria: 1. Primary or secondary plasma cell leukemia; 2. Previous treatment for MM; 3. Allergic to experimental drugs, such as bortezomib and lenalidomide; 4. Patient has participated in another clinical trial or received any type of research drug; 5. HIV positive.

Design outcomes

Primary

Measure	Time frame
Overall survival;	—

Secondary

Measure	Time frame
minimal residual disease;adverse events;progress free survival;Functional Assessment of Cancer Therapy-General (FACT-G) score;	—

Countries

China

Contacts

Public ContactYiying Xiong

The First Affiliated Hospital of Chongqing Medical University

xiongyiying@foxmail.com+86 15683777559

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026